Kynurenine pathway metabolism in patients with osteoporosis after 2 years of drug treatment

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 11, 2006, Pages 1078-1087

  Forrest, Caroline M ^a   Mackay, Gillian M ^a   Oxford, Lynn ^a   Stoy, Nicholas ^b   Stone, Trevor W ^a,c   Darlington, L Gail ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b EPSOM GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

3 hydroxyanthranilic acid; Anthranilic acid; Bisphosphonate; Etidronate; Indoleamines; Kynurenine; Neopterin; Osteoporosis; Raloxifene; Selective oestrogen receptor modulator; Tryptophan

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 4 HYDROXYNONENAL; ANTHRANILIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; GLUTAMATE RECEPTOR; INDOLEAMINE; KYNURENINE; MALONALDEHYDE; NEOPTERIN; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINIC ACID; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRYPTOPHAN;

ADULT; AGED; AMINO ACID METABOLISM; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSTRUMENT; LIPID PEROXIDATION; MALE; METABOLITE; OSTEOPOROSIS; OXIDATION; OXIDATIVE STRESS;

3-HYDROXYANTHRANILIC ACID; AGED; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; INDOMETHACIN; KYNURENIC ACID; KYNURENINE; LIPID PEROXIDATION; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; NEOPTERIN; OSTEOPOROSIS; SODIUM SALICYLATE; TRYPTOPHAN;

EID: 33750057660     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04490.x     Document Type: Article

References (66)

1. Okada Y, Tanaka. Y. Immune signals in the context of secondary osteoporosis. Histol. Histopathol. 2004; 19: 863-6.
2. Taylor MW, Feng GS. Relationship between interferon-γ, indoleamine-2,3-dioxygenase and tryptophan catabolism. FASEB J. 1991; 5: 2516-22.
3. Stone TW. The neuropharmacology of quinolinic acid and kynurenic acids. Pharmacol. Rev. 1993; 45: 309-79.
4. Stone TW. Kynurenines in the CNS: From obscurity to therapeutic relevance. Progr. Neurobiol. 2001; 64: 185-218.
5. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat. Drug Discov. 2002; 1: 609-20.
6. Stone TW, Perkins MN. Quinolinic acid: A potent endogenous excitant at amino acid receptors in the CNS. Eur. J. Pharmacol. 1981; 72: 411-12.
7. Perkins MN, Stone TW. An iontophoretic investigation of the action of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 1983; 247: 184-7.
8. Gill SS, Mueller RW, McGuire RF, Pulido OM. Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity. Toxicol. Pathol. 2000; 28: 277-84.
9. Chenu C, Serre CM, Raynal C, Burt-Richat B, Delmas PD. Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone 1998; 22: 295-9.
10. Mason DJ, Suva LJ, Genever PG et al. Mechanically regulated expression of a neural glutamate transporter in bone: A role for excitatory amino acids as osteotropic agents? Bone 1997; 20: 199-205.
11. Patton AJ, Genever PG, Birch MA, Suva LJ, Skerry TM. Expression of an NMDA type receptor by human and rat osteoblasts suggests a novel glutamate signalling pathway in bone. Bone 1998; 22: 645-9.
12. Eastman CL, Guilarte TR. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem. Res. 1990; 15: 1101-7.
13. Okuda S, Nishiyama N, Saito H, Katsuki H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc. Natl Acad. Sci. USA 1996; 93: 12 553-8.
14. Thomas SR, Stocker R. Redox reactions related to indoleamine-2,3- dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep. 1999; 4: 199-220.
15. Evans CH, Stefanovicracic M, Lancaster J. Nitric oxide and its role in orthopaedic disease. Clin. Orthop. Relat. Res. 1995; 312: 275-94.
16. Cardinali DP, Ladizesky MG, Boggio V. Melatonin effects on bone: Experimental facts and clinical perspectives. Pineal Res. 2003; 34: 81-7.
17. Schori H, Yoles E, Wheeler LA, Raveh T, Kimchi A, Schwartz M. Immune-related mechanisms participating in resistance and susceptibility to glutamate toxicity. Eur. J. Neurosci. 2002; 16: 557-64.
18. Forrest CM, Kennedy A, Stone TW, Stoy N, Darlington LG. Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. Adv. Exp. Med. Biol. 2003; 527: 287-95.
19. Iwata H, Okamoto H, Ko S. Effects of various drugs on serum free and total tryptophan levels and brain tryptophan metabolism in rats. Jpn. J. Pharmacol. 1975; 25: 303-10.
20. Kragh-Hansen A. Relations between high-affinity binding sites of L-tryptophan, diazepam, salicylate and phenol red on human serum albumin. Biochem. J. 1983; 209: 35-42.
21. Lui EM, Farmer PS, Dean CR. Functional modification of indole binding site with indomethacin congeners. J. Pharm. Sci. 1997; 66: 950-5.
22. Badawy AA. Mechanisms of elevation of rat brain tryptophan concentration by various doses of salicylate. Br. J. Pharmacol. 1982; 76: 211-13.
23. World Health Organization. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Technical Report Series 843. WHO, Geneva. 1994.
24. Delmas PD, Bjarnason NH, Mitlar BH et al. Effects of raloxifene on bone mineral density serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997; 337: 1641-7.
25. Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. 2000; 85: 3109-15.
26. Mühlbauer RC, Li F. Effect of vegetables on bone metabolism. Nature 1999; 40: 343-4.
27. Herve C, Beyne P, Jamault H, Delacoux E. Determination of tryptophan and its kynurenine pathway metabolites in human serum by HPLC with simultaneous UV and fluorimetric detection. J. Chromatogr. 1996; 675: 157-61.
28. Cannazza G, Baraldi M, Braghiroli D, Tait A, Parenti C. High performance liquid chromatography method for the quantification of anthranilic and 3-hydroxyanthranilic acid in rat brain dialysate. J. Pharm. Biomed. Anal. 2003; 32: 287-93.
29. Shibata K. Fluorimetric micro-determination of kynurenic acid, an endogenous blocker of neurotoxicity, by HPLC. J. Chromatogr. Biomed. 1988; 430: 376-80.
30. Murr C, Hainz U, Asch E et al. Increased neopterin concentration in older age coincides with decline of CD28(+) CD45RA(+) T-cells. Pteridines 2004; 15: 170-4.
31. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin. Biochem. 2004; 37: 684-7.
32. Graham DY. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig. Dis. Sci. 2002; 47: 1665-78.
33. Heyes MP, Saito K, Devinsky O, Nadi NS. Kynurenine pathway metabolites in CSF and serum in complex partial seizures. Epilepsia 1994; 35: 251-7.
34. Huengsberg M, Winer JB, Gompels M, Round R, Ross J, Shahmanesh M. Serum-to-kynurenine ratio increases with progressive disease in HIV-infected patients. Clin. Chem. 1998; 44: 858-62.
35. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J. Neural Transm. 2000; 107: 343-53.
36. Widner B, Sepp N, Kowald E et al. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 2000; 201: 621-30.
37. Kazda H, Taylor N, Healy D, Walker D. Maternal, umbilical and amniotic fluid concentrations of tryptophan and kynurenine after labor or cesarean section. Pediatr. Res. 1998; 44: 368-73.
38. Saito K, Fujigaki S, Heyes MP et al. Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency. Am. J. Physiol. Renal Physiol. 2000; 279: F565-72.
39. Truscott RJ, Elderfield AJ. Relationship between serum tryptophan and tryptophan metabolite levels after tryptophan ingestion in normal subjects and age-related cataract patients. Clin. Sci. 1995; 89: 591-9.
40. Elefteriou F. Neuronal signaling and the regulation of bone remodelling. Cell. Mol. Life Sci. 2005; 62: 2339-49.
41. Hinoi E, Fujimori S, Nakamura Y, Yoneda Y. Functional expression of NMDA receptors in cultured rat calvarial osteoblasts. J. Neurochem. 2001; 78: 174 (Abstract).
42. Ho ML, Tsai TN, Chang JK, Shao TS, Jeng YR, Hsu C. Down-regulation of N-methyl-D-aspartate receptor in rat-modeled disuse osteopenia. Osteoporos. Int. 2005; 16: 1780-8.
43. Itzstein C, Cheynel H, Burt-Pichat B et al. Molecular identification of NMDA glutamate receptors expressed in bone cells. J. Cell. Biochem. 2001; 82: 134-44.
44. Merle B, Itzstein C, Delmas PD, Chenu C. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. J. Cell. Biochem. 2003; 90: 424-36.
45. Park BG, Yoo CI, Kim HT, Kwon CH, Kim YK. Role of mitogen-activated protein kinases in hydrogen peroxide-induced cell death in osteoblastic cells. Toxicology 2005; 215: 115-25.
46. Fatokun AA, Stone TW, Smith RA. Aspects of glutamate signalling in bone: Hydrogen peroxide-induced oxidative stress in the osteoblast-like MC3T3-E1 cell line. Free Radic. Res. 2005; 39 (Suppl. 1): S86 (Abstract).
47. Chen RM, Chen TL, Chiu WT, Chang CC. Molecular mechanism of nitric oxide-induced osteoblast apoptosis. J. Orthop. Res. 2005; 23: 462-8.
48. Bai XC, Lu D, Bai J et al. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappa B. Biochem. Biophys. Res. Commun. 2004; 314: 197-207.
49. Lee YS, Chen XW, Anderson JJB. Physiological concentrations of genistein stimulate the proliferation and protect against free radical-induced oxidative damage of MC3T3-E1 osteoblast-like cells. Nutr. Res. 2001; 21: 1287-98.
50. Liu AL, Zhang ZM, Zhu BF, Liao ZH, Liu Z. Metallothionein protects bone marrow stromal cells against hydrogen peroxide-induced inhibition of osteoblastic differentiation. Cell Biol. Int. 2004; 28: 905-11.
51. Chacksfield MA, Zimmerman N, Hodge JM et al. Oxidative stress accelerates human osteoclast differentiation: Possible role of thioredoxin. J. Bone Miner. Res. 2004; 19: S414 (Abstract).
52. Lean JM, Davies JT, Fuller K et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J. Clin. Invest. 2003; 112: 915-23.
53. Goldstein LE, Leopold MC, Huang XD et al. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry 2000; 39: 7266-75.
54. Giles GI, Collins CA, Stone TW, Jacob C. Electrochemical and in vitro evaluation of the redox properties of kynurenine species. Biochem. Biophys. Res. Commun. 2003; 300: 719-24.
55. Thomas SR, Witting PK, Stocke R. 3-Hydroxyanthranilic acid is an efficient, cell-derived co-oxidant for α-tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation. J. Biol. Chem. 1996; 271: 32 714-21.
56. Goda K, Hamane R, Kishimoto R, Ogishi Y. Radical scavenging properties of tryptophan metabolites. Adv. Exp. Med. Biol. 1999; 467: 397-402.
57. Oh GS, Pae HO, Choi BM et al. 3-Hydroxy-anthranilic acid, one of the metabolites of tryptophan via indoleamine 2,3-dioxygenase pathway, suppresses inducible nitric oxide synthase expression by enhancing heme oxygenase-expression. Biochem. Biophys. Res. Commun. 2004; 320: 1156-62.
58. Morita T, Saito K, Takemura M et al. 3-Hyroxyanthranilic acid, an L-tryptophan metabolite induces apoptosis in monocyte-derived cells stimulated by interferon-gamma. Ann. Clin. Biochem. 2001; 38: 242-51.
59. Morita T, Saito K, Takemura M et al. L-tryptophan-kynurenine pathway metabolite 3-hydroxyanthranilic acid induced apoptosis in macrophage-derived cells under pathophysiological conditions. Adv. Exp. Med. Biol. 1999; 467: 559-63.
60. Kumitomo M, Tanaka Y, Yamada K, Yamaguchi Y, Bando Y. Enhancing activity of anthranilic acid on adjuvant arthritis in rats and antibody formation in mice. Jpn. J. Pharmacol. 1989; 50: 507-10.
61. Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 2000; 347: 1-16.
62. Aylward M. Oestrogens, plasma tryptophan levels in peri menopausal patients. In: Campbell S (ed.). The Management of the Menopause and Post-Menopause Years. MTP Press, Lancaster. 1976; 135-47.
63. Rose DP, Brandman IP. Excretion of tryptophan metabolites as affected by pregnancy, contraceptive steroids and steroid hormones. Am. J. Clin. Nutr. 1971; 24: 673-83.
64. 6 requirements. Clin. Sci. 1972; 42: 465-77.
65. Wolf H, Walter S, Brown RR, Arend RA. Effect of natural oestrogens on tryptophan metabolism: Evidence for interference of oestrogens with kynureninase. Scand. J. Clin. Lab. Invest. 1986; 40: 15-22.
66. Mason M, Ford J, Wu. HL. Effects of steroid and nonsteroid metabolites on enzyme conformation and pyridoxal phosphate binding. Ann. N.Y. Acad. Sci. 1969; 166: 170-83.